Where you are treated matters more than almost anything
The single most important thing on this page: sarcomas should be diagnosed and treated at a specialist sarcoma centre, and the biopsy should be planned by the surgeon who will do the operation. A biopsy placed in the wrong direction, or a lump "shelled out" by a well-meaning surgeon who assumed it was benign, can turn a limb-sparing operation into a much bigger one. This happens often enough to have a name in the literature — the "whoops procedure." If you have a deep lump larger than about 5 cm, or any lump that is growing, ask for referral before anything is cut.
For bone tumours specifically, an X-ray is usually the first test and is often enough to raise suspicion. If an X-ray looks worrying, the next step is referral — not a local biopsy. Ask to be sent to a centre that treats sarcoma regularly.
Who is at risk
- Age — osteosarcoma and Ewing sarcoma peak in teenagers and young adults, during the growth spurt; chondrosarcoma occurs in older adults.
- Previous radiation therapy to the area, usually many years earlier.
- Inherited conditions — hereditary retinoblastoma (RB1), Li-Fraumeni syndrome (TP53), Rothmund-Thomson syndrome, and multiple hereditary exostoses or enchondromatosis (which predispose to chondrosarcoma).
- Paget's disease of bone in older adults.
- Previous chemotherapy with alkylating agents.
- Most people have none of these. Bone cancer is not caused by injury — though an injury often draws attention to a bone that was already abnormal, which is why 'it started after I hurt it' is such a common and misleading history.
Finding it early
There is no screening test, and bone cancer is far too rare to screen for. Early detection depends entirely on taking persistent bone pain seriously.
The pattern that matters:
- Bone pain that is worse at night or at rest — not the pain of activity. This is the classic feature and the most commonly dismissed one.
- Pain lasting more than a few weeks that does not respond to ordinary painkillers or rest.
- A firm swelling or lump over a bone, particularly near the knee, upper arm or pelvis.
- A bone that breaks with little or no force (pathological fracture).
- Unexplained fever or weight loss with bone pain — more typical of Ewing sarcoma.
Teenage "growing pains" are common and usually harmless. Growing pains do not persist in one spot, do not cause swelling, and do not steadily worsen. Persistent pain in one bone, especially at night, warrants an X-ray.
How it’s diagnosed
X-ray first — often highly suggestive on its own. Then MRI of the whole affected bone to define the extent, plus CT chest and a bone scan or PET/CT to check for spread (the lungs are the most common site).
The biopsy must be planned by the sarcoma surgical team. The needle track has to sit where it can be removed with the tumour at the definitive operation. This is not bureaucratic caution — a badly placed biopsy can cost a limb.
Specialist bone pathology matters too: distinguishing osteosarcoma, Ewing sarcoma, chondrosarcoma and benign lesions requires experience, and molecular testing (EWSR1 rearrangement in Ewing sarcoma) confirms the diagnosis.
Staging explained simply
Bone sarcomas are staged by grade, size, and whether the cancer has spread. In practice the division that drives treatment is simpler: localized (confined to the bone and nearby tissue) versus metastatic (spread, usually to the lungs).
Localized disease is treated with cure as the clear goal. Metastatic disease is harder, but — unusually — cure remains possible for some patients with lung-only spread that can be surgically removed, so aggressive treatment is often still appropriate.
Response to chemotherapy is itself a powerful prognostic factor: in osteosarcoma, the percentage of tumour killed by pre-operative chemotherapy (measured in the removed specimen) predicts outcome.
Grading and biology
Grade — low or high — matters enormously. Osteosarcoma is typically high grade, occurs around the knee and shoulder in teenagers, and is treated with chemotherapy and surgery. Ewing sarcoma is high grade, driven by an EWSR1 gene fusion, affects bone and sometimes soft tissue in children and young adults, and — importantly — is radiation-sensitive. Chondrosarcoma occurs in older adults, is often low grade, and is largely resistant to both chemotherapy and conventional radiation, so surgery is the mainstay.
That difference in radiation sensitivity is why the same word — "bone cancer" — leads to completely different treatment plans.
How it’s treated
Osteosarcoma: chemotherapy first, then surgery to remove the tumour, then more chemotherapy. Limb-sparing surgery is possible for the large majority — amputation is now the exception rather than the rule, though it is sometimes the better functional choice and that deserves an honest conversation rather than assumption. Radiation has a limited role because osteosarcoma is relatively radioresistant, but it is used when surgery is not possible or margins are positive.
Ewing sarcoma: chemotherapy, then local treatment which may be surgery, radiation, or both — Ewing sarcoma is genuinely radiosensitive, so radiation is a curative local treatment here, not a fallback. Then more chemotherapy. Total treatment typically runs close to a year.
Chondrosarcoma: surgery is the treatment; chemotherapy and conventional radiation are largely ineffective. Proton or carbon-ion therapy is used for chondrosarcoma and chordoma at the skull base and spine, where surgery cannot achieve clear margins — a specific and valuable application.
Where CureRays fits: honestly, it depends entirely on the type. In Ewing sarcoma radiation is curative treatment. In chondrosarcoma of the skull base, particle therapy is the answer. In osteosarcoma, radiation is a supporting player and we will say so.
What the guidelines say
In broad strokes: refer suspected bone sarcoma to a specialist centre before biopsy; image the whole bone with MRI and stage the chest; give chemotherapy before and after surgery for osteosarcoma and Ewing sarcoma; achieve wide surgical margins with limb-sparing reconstruction where possible; use radiation as definitive local treatment in Ewing sarcoma and particle therapy for skull-base and spinal chondrosarcoma and chordoma; and treat within a multidisciplinary sarcoma team.
Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The above is a plain-language overview of the general approach, not the guideline itself. NCCN publishes free NCCN Guidelines for Patients®.
Outcomes and odds of cure
Five-year relative survival for bone and joint cancer is approximately 71% (NCI SEER, SEER 21 excluding IL, 2015–2021). In 2025 an estimated 3,770 people will be diagnosed and about 2,190 will die of it. Source: SEER Cancer Stat Facts: Bone and Joint Cancer.
SEER does not publish a localized/regional/distant survival table for bone cancer, so we are not showing one. The clinically meaningful split is localized versus metastatic disease, and outcomes differ sharply between them and between tumour types — ask your sarcoma team for figures matched to your type, grade, site and whether it has spread.
One trend worth naming honestly: bone cancer death rates have been rising about 1.8% a year (SEER, 2014–2023) even as survival for many other cancers improves. Progress in osteosarcoma in particular has been slow for decades, which is a strong argument for asking about clinical trials.
These are population statistics from the National Cancer Institute's SEER program. They describe large groups of people, not any one person, and lag current treatment by several years. They cannot predict what will happen to you.
Side effects and how we watch for them
Because so many patients are teenagers and young adults who will be cured, long-term effects drive treatment decisions here more than in most cancers.
Chemotherapy: doxorubicin affects the heart (lifetime dose is tracked and echocardiograms continue for years); cisplatin causes hearing loss and kidney effects — report hearing changes immediately, because dose can be adjusted; methotrexate needs careful monitoring. Fertility is affected, and preservation must be discussed before treatment starts — for a 15-year-old this is an awkward conversation that matters for the next 60 years.
Surgery: limb-sparing reconstruction may need revision operations over a lifetime, particularly in a growing child. Function takes months of rehabilitation.
Radiation in a growing child can affect bone growth and carries a small long-term second-cancer risk — which is precisely why proton therapy is often preferred in paediatric cases.
How it is assessed: graded at each visit on a standard scale, with cardiac, hearing, kidney and growth monitoring built into the schedule.
Follow-up, remission and survivorship
Remission means no detectable cancer. Follow-up combines examination, imaging of the primary site and regular chest imaging, because the lungs are where bone sarcomas recur. Surveillance is most intense in the first two to three years and continues for at least ten.
Survivorship is a decades-long project for these patients: cardiac function after anthracyclines, hearing, fertility, bone health, limb function and implant revision, second cancers, and the psychological and educational impact of losing a year of adolescence to treatment. A written survivorship plan naming who monitors what is genuinely important here.
Questions people actually ask
My teenager has knee pain from sport. Should I worry?
Usually not — sports injuries are far more common. What distinguishes concerning pain is that it is worse at night or at rest, persists in one spot for weeks, does not improve with rest, or comes with swelling. That pattern warrants an X-ray.
Will my child lose their leg?
Probably not. Limb-sparing surgery is possible for the large majority of bone sarcomas today. Amputation is sometimes the better functional choice for particular tumours or ages, and that deserves a real discussion rather than an assumption either way.
Why do we have to travel to a specialist centre?
Because outcomes are measurably better, and because the biopsy itself must be planned by the team who will operate. A biopsy in the wrong place can turn a limb-sparing operation into an amputation. This is the one referral worth insisting on.
Does radiation work for bone cancer?
It depends entirely on the type. Ewing sarcoma is genuinely radiosensitive and radiation can be curative local treatment. Osteosarcoma is relatively radioresistant, so radiation plays a supporting role. Chondrosarcoma at the skull base is treated with proton or carbon-ion therapy.
He hurt it playing football and then we found this. Did the injury cause it?
No. Injuries do not cause bone cancer — but an injury often draws attention to a bone that was already weakened or abnormal. It is a very common history and it does not mean anything was done wrong.
Related pages
See also Keep Sarcoma Away® for soft tissue sarcomas, and Keep Childhood Cancer Away® for cancer in children and teenagers.
Informational only, not medical advice — confirm with your care team.
Chronic side effects of radiation in the spine
Go deeper on bone cancer
Read the full plain-language guide, or ask our team where radiation fits for your tumour type.